Connection

GUILLERMINA LOZANO to Proto-Oncogene Proteins

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Proto-Oncogene Proteins.
Connection Strength

6.007
  1. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6622-6629.
    View in: PubMed
    Score: 0.361
  2. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.296
  3. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol. 2017 03; 241(4):501-510.
    View in: PubMed
    Score: 0.290
  4. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res. 2016 Jan; 14(1):56-65.
    View in: PubMed
    Score: 0.267
  5. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget. 2014 Mar 15; 5(5):1149-56.
    View in: PubMed
    Score: 0.239
  6. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat. 2014 Jun; 35(6):728-37.
    View in: PubMed
    Score: 0.238
  7. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 2013 Jan 01; 19(1):34-41.
    View in: PubMed
    Score: 0.219
  8. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010 Sep 15; 70(18):7148-54.
    View in: PubMed
    Score: 0.186
  9. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation. 2009 Jun; 77(5):442-9.
    View in: PubMed
    Score: 0.170
  10. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008 Jun; 6(6):947-54.
    View in: PubMed
    Score: 0.160
  11. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62.
    View in: PubMed
    Score: 0.151
  12. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation. 2007 Jun 12; 115(23):2925-30.
    View in: PubMed
    Score: 0.149
  13. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol. 2007 Aug; 27(15):5479-85.
    View in: PubMed
    Score: 0.149
  14. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 2006 Oct 01; 66(19):9502-8.
    View in: PubMed
    Score: 0.142
  15. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006 Jun; 13(6):927-34.
    View in: PubMed
    Score: 0.139
  16. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3226-31.
    View in: PubMed
    Score: 0.136
  17. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol. 2006 Jan; 26(1):192-8.
    View in: PubMed
    Score: 0.135
  18. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell. 2005 Jul; 8(1):3-4.
    View in: PubMed
    Score: 0.130
  19. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene. 2004 Oct 07; 23(46):7644-50.
    View in: PubMed
    Score: 0.124
  20. Model predictions of MDM2 mediated cell regulation. Cell Cycle. 2004 May; 3(5):655-61.
    View in: PubMed
    Score: 0.121
  21. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003 Dec 15; 63(24):8664-9.
    View in: PubMed
    Score: 0.117
  22. MDM2, an introduction. Mol Cancer Res. 2003 Dec; 1(14):993-1000.
    View in: PubMed
    Score: 0.117
  23. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002 May 16; 21(22):3525-31.
    View in: PubMed
    Score: 0.105
  24. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis. 2002 Feb; 32(2):145-7.
    View in: PubMed
    Score: 0.103
  25. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001 Sep; 29(1):92-5.
    View in: PubMed
    Score: 0.100
  26. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001 Jul 05; 20(30):4041-9.
    View in: PubMed
    Score: 0.099
  27. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83.
    View in: PubMed
    Score: 0.098
  28. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell. 2021 04 12; 39(4):529-547.e7.
    View in: PubMed
    Score: 0.097
  29. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000 Mar 23; 19(13):1691-7.
    View in: PubMed
    Score: 0.091
  30. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8.
    View in: PubMed
    Score: 0.086
  31. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999 Mar; 10(3):147-54.
    View in: PubMed
    Score: 0.084
  32. MDM2 function. Biochim Biophys Acta. 1998 Apr 17; 1377(2):M55-9.
    View in: PubMed
    Score: 0.079
  33. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene. 1997 Sep 25; 15(13):1527-34.
    View in: PubMed
    Score: 0.076
  34. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet. 1997 Aug; 16(4):336-7.
    View in: PubMed
    Score: 0.075
  35. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb Perspect Med. 2016 08 01; 6(8).
    View in: PubMed
    Score: 0.070
  36. The organization and expression of the mdm2 gene. Genomics. 1996 May 01; 33(3):352-7.
    View in: PubMed
    Score: 0.069
  37. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016 09 08; 35(36):4798-806.
    View in: PubMed
    Score: 0.068
  38. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
    View in: PubMed
    Score: 0.067
  39. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 09; 378(6553):203-6.
    View in: PubMed
    Score: 0.067
  40. Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ. 1994 Oct; 5(10):1023-31.
    View in: PubMed
    Score: 0.062
  41. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):11995-2000.
    View in: PubMed
    Score: 0.049
  42. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010 May 26; 5(5):e10813.
    View in: PubMed
    Score: 0.046
  43. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.036
  44. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood. 2007 Mar 15; 109(6):2630-3.
    View in: PubMed
    Score: 0.036
  45. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol. 2006 Jun; 16(3):225-34.
    View in: PubMed
    Score: 0.034
  46. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 2004 Dec 15; 64(24):9080-5.
    View in: PubMed
    Score: 0.031
  47. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.031
  48. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003 Mar 21; 112(6):779-91.
    View in: PubMed
    Score: 0.028
  49. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003 Mar; 21(3):321-6.
    View in: PubMed
    Score: 0.028
  50. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene. 2002 Oct 10; 21(46):7100-13.
    View in: PubMed
    Score: 0.027
  51. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002 May 31; 277(22):19251-4.
    View in: PubMed
    Score: 0.026
  52. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999 Apr 01; 18(7):1805-14.
    View in: PubMed
    Score: 0.021
  53. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res. 1997 Aug; 148(2):115-22.
    View in: PubMed
    Score: 0.019
  54. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997 Mar 15; 11(6):714-25.
    View in: PubMed
    Score: 0.018
  55. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 1996 Oct 17; 13(8):1731-6.
    View in: PubMed
    Score: 0.018
  56. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010 Dec; 23(6):781-94.
    View in: PubMed
    Score: 0.012
  57. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol. 2005 Jun; 19(6):1646-53.
    View in: PubMed
    Score: 0.008
  58. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000 Sep 15; 14(18):2358-65.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.